120 related articles for article (PubMed ID: 38893073)
61. Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
Battisti NML; Reed MWR; Herbert E; Morgan JL; Collins KA; Ward SE; Holmes GR; Bradburn M; Walters SJ; Burton M; Lifford K; Edwards A; Robinson TG; Martin C; Chater T; Pemberton KJ; Shrestha A; Brennan A; Cheung KL; Todd A; Audisio RA; Wright J; Simcock R; Green T; Revell D; Gath J; Horgan K; Holcombe C; Winter MC; Naik J; Parmeshwar R; Gosney MA; Hatton MQ; Thompson AM; Wyld L; Ring A;
Eur J Cancer; 2021 Feb; 144():269-280. PubMed ID: 33373871
[TBL] [Abstract][Full Text] [Related]
62. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
Ripping TM; Rammant E; Witjes JA; Aaronson NK; van Hemelrijck M; van Hoogstraten LMC; ; Kiemeney LA; Aben KKH
Health Qual Life Outcomes; 2022 Dec; 20(1):171. PubMed ID: 36581934
[TBL] [Abstract][Full Text] [Related]
63. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Chase DM; Marín MR; Backes F; Han S; Graybill W; Mirza MR; Pothuri B; Mangili G; O'Malley DM; Berton D; Willmott L; Baumann K; Coleman RL; Safra T; Heinzelmann-Schwarz V; Lorusso D; Karl FM; Woodward T; Monk BJ; Gonzalez-Martin A;
Gynecol Oncol; 2022 Sep; 166(3):494-502. PubMed ID: 35851489
[TBL] [Abstract][Full Text] [Related]
64. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.
Crott R; Briggs A
Eur J Health Econ; 2010 Aug; 11(4):427-34. PubMed ID: 20473703
[TBL] [Abstract][Full Text] [Related]
65. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
66. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
[TBL] [Abstract][Full Text] [Related]
67. Psychometric properties of the EQ-5D-5L compared with EQ-5D-3L in cancer patients in Iran.
Moradi N; Poder TG; Safari H; Mojahedian MM; Ameri H
Front Oncol; 2022; 12():1052155. PubMed ID: 36568223
[TBL] [Abstract][Full Text] [Related]
68. Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health.
Crick K; Al Sayah F; Ohinmaa A; Johnson JA
Qual Life Res; 2018 Jun; 27(6):1625-1633. PubMed ID: 29516342
[TBL] [Abstract][Full Text] [Related]
69. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
70. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.
Kvam AK; Fayers PM; Wisloff F
Eur J Haematol; 2011 Oct; 87(4):330-7. PubMed ID: 21668504
[TBL] [Abstract][Full Text] [Related]
71. Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease.
Leeneman B; Blommestein HM; van Dongen-Leunis A; Algeri M; Fibbe WE; Oosten L; Uyl-de Groot CA; Thielen FW
Eur J Haematol; 2023 Aug; 111(2):240-246. PubMed ID: 37137484
[TBL] [Abstract][Full Text] [Related]
72. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
73. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness.
Bilbao A; García-Pérez L; Arenaza JC; García I; Ariza-Cardiel G; Trujillo-Martín E; Forjaz MJ; Martín-Fernández J
Qual Life Res; 2018 Nov; 27(11):2897-2908. PubMed ID: 29978346
[TBL] [Abstract][Full Text] [Related]
74. Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation.
Chen P; Lin KC; Liing RJ; Wu CY; Chen CL; Chang KC
Qual Life Res; 2016 Jun; 25(6):1585-96. PubMed ID: 26714699
[TBL] [Abstract][Full Text] [Related]
75. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients.
Lee CF; Luo N; Ng R; Wong NS; Yap YS; Lo SK; Chia WK; Yee A; Krishna L; Wong C; Goh C; Cheung YB
Qual Life Res; 2013 Sep; 22(7):1745-51. PubMed ID: 23054499
[TBL] [Abstract][Full Text] [Related]
76. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
Lamu AN; Björkman L; Hamre HJ; Alræk T; Musial F; Robberstad B
Health Qual Life Outcomes; 2021 Apr; 19(1):125. PubMed ID: 33865400
[TBL] [Abstract][Full Text] [Related]
77. Translation and validation of the Urdu version of the European organization for research and treatment of cancer core quality of life questionnaire (EORTC QLQ-C30) and brain module (QLQ-BN20) in primary brain tumor patients.
Zahid N; Martins RS; Zahid W; Khalid W; Azam I; Bhamani SS; Asad N; Ahmad K; Jabbar AA; Shamim MS; Khan RJ; Javed G; Bari E; Enam SA
J Patient Rep Outcomes; 2021 Sep; 5(1):79. PubMed ID: 34487251
[TBL] [Abstract][Full Text] [Related]
78. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
[TBL] [Abstract][Full Text] [Related]
79. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
80. Quality of life of caregivers of breast cancer patients: a cross-sectional evaluation.
Clarijs ME; Oemrawsingh A; Bröker MEE; Verhoef C; Lingsma H; Koppert LB
Health Qual Life Outcomes; 2022 Feb; 20(1):29. PubMed ID: 35183212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
